[The experience in dutasteride use before transurethral prostatic resection for large adenoma]

Area of Science:

• Urology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is common in older men.
• Transurethral resection of the prostate (TUR) is a standard treatment for BPH.
• Hemorrhagic complications can occur during and after TUR.

Purpose of the Study:

• To evaluate the efficacy of dutasteride in preventing intra- and postoperative hemorrhagic complications before TUR.
• To assess the impact of dutasteride on surgical outcomes in patients with large prostatic adenoma.

Main Methods:

• A randomized trial involving 70 males aged 67-82 years with prostatic adenoma (>80 cm3).
• Group 1 received dutasteride (0.5 mg/day) and tamsulosin.
• Group 2 received only tamsulosin.

Main Results:

• Dutasteride group showed significantly less intraoperative blood loss (93.6 ml vs. 138.6 ml, p < 0.05).
• Shorter operation duration, less irrigation fluid, and reduced catheterization time were observed in the dutasteride group.
• Hospitalization and urinary drainage times were also reduced; no postoperative hemorrhagic complications occurred.

Conclusions:

• Dutasteride (0.5 mg/day for 1 month) is recommended for preventing hemorrhagic complications before TUR.
• It improves surgical conditions and outcomes, even for smaller prostates (30-80 cm3).